Semaglutide for Weight Loss: Results, Timeline and Before-and-After

The FDA-approved semaglutide product for weight management is the branded prescription drug Wegovy, approved, with diet and activity, to reduce and maintain excess body weight in adults and children 12+ with obesity and in adults with overweight plus at least one weight-related condition.

The drug itself, its cost and its safety profile are covered in our semaglutide guide; this page is about results — how much, how fast, and what happens after.

For how it compares with tirzepatide, see semaglutide vs tirzepatide.

The headline numbers come from STEP 1 (Wilding et al., NEJM 2021), which tested semaglutide 2.4 mg against placebo for 68 weeks in adults with overweight or obesity and no diabetes, alongside a lifestyle intervention.

Mean body-weight change at week 68 was -14.9% with semaglutide (-15.3 kg) versus -2.4% with placebo (-2.6 kg).

86.4% of the semaglutide participants lost at least 5% of their body weight, and 50.5% lost at least 15%.

Those are trial averages, measured over 68 weeks with structured lifestyle counseling — not a forecast of what any one patient will lose.

Results ran smaller in people with type 2 diabetes: in STEP 2, weight change at 68 weeks was -9.6% versus -3.4% on placebo.

Wegovy also now comes as a daily tablet (25 mg once daily at maintenance), approved for weight reduction and cardiovascular risk reduction in adults; the label's indications were updated 12/2025.

In the label's Study 7 (64 weeks), the 25 mg tablet produced a -13.6% mean weight change versus -2.4% on placebo.

If you have searched for a month-by-month semaglutide timeline, the honest answer comes first: no label or trial source we reviewed publishes month-by-month weight figures in quotable text, and we will not invent them.

What the sources do document is the dosing schedule and the total trial lengths, and together they explain why the results read as slow and gradual.

The Wegovy label raises the weekly injection dose in steps across the first 16 weeks of treatment:

The label titrates slowly because gastrointestinal side effects were most often reported during dose escalation.

Beyond the schedule, weight loss accrued gradually over the 68-to-72-week trials rather than in monthly chunks.

One trial does document an earlier checkpoint: STEP 4 (Rubino et al., JAMA 2021, n=803) began with a 20-week run-in on semaglutide, and the mean loss during that run-in was 10.6%.

So if you are asking how fast semaglutide works: the injection trials' headline totals were measured at 68 to 72 weeks rather than month by month, we could not confirm a verified 4-week figure to quote, and your prescriber is the right person to set expectations for your first weeks.

Not everyone loses a large amount on semaglutide, and the same STEP 1 numbers show it: 86.4% of participants on semaglutide lost at least 5% of their body weight, which means the trial also contained people who lost less.

Diagnosis is one documented factor: people with type 2 diabetes lost less — -9.6% versus -3.4% on placebo at 68 weeks in STEP 2, against -14.9% in the trial of people without diabetes.

Tolerance is another: in the Wegovy weight trials, 6.8% of people on 2.4 mg stopped permanently because of adverse reactions, versus 3.2% on placebo, most commonly nausea, vomiting and diarrhea — and someone who stops is no longer taking the drug those results were measured on.

Timing matters too: the first 16 weeks are starter doses, so a month-one comparison against a 68-week trial average compares different stages of treatment.

On plateaus, we could not find a label or trial source that documents a standard protocol for restarting weight loss after a plateau, so we cannot describe one — be cautious of any program that markets a proprietary one.

What the label does document is one escalation option: adults who have tolerated 2.4 mg for at least 4 weeks can increase to Wegovy HD 7.2 mg once weekly when more weight reduction is clinically indicated.

In the label's Study 8 (72 weeks, adults with obesity without diabetes), mean weight change was -18.8% on 7.2 mg, versus -15.5% on 2.4 mg and -3.9% on placebo.

Any dose change is a decision for you and your prescriber, based on your response and medical history.

The stopping data are the most sobering results on this page.

In STEP 4, participants who switched from semaglutide to placebo at week 20 regained 6.9% body weight between weeks 20 and 68, while those who continued on the drug lost a further 7.9%.

The STEP 1 extension (n=327) followed participants after semaglutide 2.4 mg and the lifestyle program stopped: one year later, those who had been on semaglutide had regained about two-thirds of the weight they had lost, with net loss falling from 17.3% at week 68 to 5.6% at week 120.

The same paper found the participants' cardiometabolic improvements had largely reverted.

Read those as what happened to those trial groups — not as a prediction for any individual reader.

The approved use itself anticipates ongoing treatment: Wegovy is approved both to reduce excess body weight and to maintain the reduction long term, alongside diet and activity.

We do not treat reviews, testimonials or Reddit threads as evidence, because individual anecdotes cannot be verified — but each of the subjects a review might raise — how much came off, how fast, side effects, regain after stopping — has trial data behind it.

On how much: STEP 1's own thresholds show the range — 86.4% of participants on semaglutide lost at least 5% and 50.5% lost at least 15% — so a dramatic review and a modest one can both sit inside the same trial's results.

On speed: the injection trials' headline totals were measured at 68 to 72 weeks, and no source we reviewed publishes a month-one figure, so a review quoting a precise first-month number is quoting something those sources do not.

On side effects: in the Wegovy 2.4 mg weight trials, nausea occurred in 44% of participants versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, and constipation 24% versus 11%.

On stopping: 6.8% of participants on 2.4 mg left the trials because of adverse reactions versus 3.2% on placebo, and the regain findings are in the section above.

A rule of thumb for reading any review, including ours: trial means describe groups, anecdotes describe single cases, and neither promises what you will experience.

Start with the prescription itself: Wegovy is a prescription-only drug — it needs a valid prescription from a licensed prescriber, and FDA tells patients to fill prescriptions at state-licensed pharmacies.

Who that prescriber can be depends on your state — for example, whether a nurse practitioner may prescribe independently follows the state's practice category, which the AANP classifies as Full, Reduced or Restricted Practice.

Our who can prescribe GLP-1s guide covers prescriber types and supervision in detail.

When you compare programs, ask exactly what you would be prescribed: a branded, FDA-approved product or a compounded one.

FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing.

FDA also lists claims that a compounded drug is the same as an FDA-approved drug among its red flags for consumers — worth remembering when a program's before-and-after photos or promises are attached to a compounded product.

The trial numbers on this page came from studies of the approved products, so ask any program you visit what its own claims are based on.